effective amount of said compound results in a blood concentration of said compound of 200-1000 ng/dl.

13. (Twice Amended) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, [or] a pharmaceutically acceptable salt of gossypol, or a combination thereof, which method comprises:

administering to said human an anti-cancer effective amount of [a] at least one compound selected from the group consisting of gossypol[, or] and a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein administration of said anti-cancer effective amount of said compound results in a blood concentration of said compound of 200-1000 ng/dl.

Please add the following new claims:

~~16~~ 4. The method of claim 1, wherein the blood concentration of said compound is 400-1000 ng/dl.

~~17~~ 5. The method of claim ~~16~~ 4, wherein said compound is gossypolone or a physiologically acceptable salt of gossypolone.

~~18~~ 6. The method of claim ~~17~~ 5, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered orally, rectally or vaginally at a dose of 50-200 mg/d.

7 ~~19~~. The method of claim 5 ~~17~~, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered parenterally at a dose of 1-5 mg/kg/d.

11 8
~~20~~. The method of claim ~~13~~, wherein the blood concentration of said compound is 400-1000 ng/dl.

12 8
~~21~~. The method of claim ~~13~~, wherein said compound is administered parenterally at a dose of 1-2 mg/d.

13 8
~~22~~. The method of claim ~~13~~, wherein said compound is administered orally at a dose of 20-100 mg/d.

14 8
~~23~~. The method of claim ~~13~~, wherein said compound is administered rectally at a dose of 40-140 mg/d.

---

REMARKS

The Present Invention

The present invention is directed to a method of treating a cancer in a human wherein the cancer is susceptible to treatment with gossypol, a pharmaceutically acceptable salt of gossypol, gossypolone, a pharmaceutically acceptable salt of gossypolone, or any combination thereof. The method comprises administering to the human an anti-cancer effective amount of one or more of the aforementioned compounds in a pharmaceutically acceptable carrier.